Expand all sections

Ozanimod

Extended indication Relapsing multiple sclerosis
Therapeutic value No judgement
Total cost 10,200,000.00
Registration phase Clinical trials

Product

Active substance Ozanimod
Domain Neurological disorders
Main indication Multiple sclerosis
Extended indication Relapsing multiple sclerosis
Manufacturer celgene
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Extramural (GVS)
Additional remarks Toedieningsvorm: naast een Capsule-vorm komt Ozanimod ook als vloeistof beschikbaar voor kinderen (bron EMA).

Registration

Registration route Centralised (EMA)
Particularity New medicine
Submission date October 2018
Expected Registration August 2019
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement
Frequency of administration 1 times a day
Dosage per administration 0,5-1 mg

Expected patient volume per year

Patient volume

400 - 800

Market share is generally not included unless otherwise stated.
References GIP databank, hersenstichting, Nationaal MS fonds.
Additional remarks Hersenstichting: In Nederland komt MS voor bij ongeveer 1 op de 1000 inwoners. Nederland telt dus ongeveer 17.000 mensen met MS. RMS komt bij ongeveer 40% van alle mensen met MS voor (6800 personen). Verwachting: minder patiënten dan Ocrevus. Inschatting reëel volume: 400-800.

Expected cost per patient per year

Cost 12,000.00 - 22,000.00
References Fabrikant
Additional remarks Prijs in lijn met directe concurrenten. Bij substitutie geen toename in kosten.

Potential total cost per year

Total cost

10,200,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.